On April 28, 2017, Brigatinib got approval by the US FDA for use in patients with ALK-positive metastatic NSCLC who are intolerant to crizotinib or whose disease has progressed after treatment. The gene discussed is ALK; the disease is non-small cell lung carcinoma.